Summit Therapeutics
SMMT
206 hedge funds and large institutions have $2.06B invested in Summit Therapeutics in 2025 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 75 increasing their positions, 65 reducing their positions, and 60 closing their positions.
15% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 65
1.42% more ownership
Funds ownership: 13.85% → 15.27% (+1.4%)
3% less capital invested
Capital invested by funds: $2.13B → $2.06B (-$65.9M)
11% less funds holding
Funds holding: 232 → 206 (-26)
28% less call options, than puts
Call options by funds: $52.1M | Put options by funds: $72.2M
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
42% less first-time investments, than exits
New positions opened: 35 | Existing positions closed: 60
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$90.9M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$83.6M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$50.2M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$42.8M |
| 5 |
BlackRock
New York
|
+$37.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$18.8M |
| 2 |
Fiera Capital (Canada)
Montreal,
Quebec, Canada
|
-$15.7M |
| 3 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$15.4M |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
-$11.4M |
| 5 |
CFM
Capricorn Fund Managers
London,
United Kingdom
|
-$10.3M |
SMMT Hedge Fund Activity: Q4 2025 in Review
206 of the 8,266 institutional investors tracked by Wall St. Rank reported a position in Summit Therapeutics (SMMT) for Q4 2025, worth a combined $2.06B — down 3.1% from $2.13B a quarter earlier.
Sellers outnumbered buyers: 60 funds closed out of SMMT and 35 opened new positions — a net loss of 25 holders — while 65 trimmed existing stakes and 75 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $90.9M. The largest seller was Morgan Stanley, cutting an estimated $18.8M.
- 206 institutional investors held Summit Therapeutics (SMMT) as of Q4 2025, down from 232 in Q3 2025.
- Funds reported $2.06B of Summit Therapeutics stock for Q4 2025, down 3.1% quarter-over-quarter.
- 35 funds opened new Summit Therapeutics positions in Q4 2025 and 60 closed out, a net change of -25 holders.
- The largest Summit Therapeutics buyer in Q4 2025 was T. Rowe Price Associates, an estimated $90.9M added.
- The largest Summit Therapeutics seller in Q4 2025 was Morgan Stanley, an estimated $18.8M sold.
Based on aggregated 13F filings for Q4 2025.